Incisive Genetics
Incisive Genetics Inc. is a Canadian biotech company dedicated to developing innovative gene delivery platforms for genetic therapies. Their mission is to address the critical challenge of effective and safe delivery of gene editing machinery into target tissues, aiming to create potentially curative therapies for serious genetic diseases. They focus on their proprietary Incisive Delivery System™ and OmniaTM platform, which are non-viral delivery methods for CRISPR-based gene therapies, enabling precise, efficient, and safe gene editing solutions.
Industries
Nr. of Employees
small (1-50)
Products
Patent-pending non-viral LNP delivery platform for CRISPR RNPs
A lipid nanoparticle-based delivery platform designed to encapsulate and deliver pre-formed CRISPR protein–guide RNA complexes (RNPs) for in vivo genome editing applications.
Preclinical CRISPR-based therapeutic candidates
Therapeutic development efforts that pair the LNP delivery platform with active endonuclease proteins and target-specific guide RNAs to create candidate treatments for genetic diseases.
Patent-pending non-viral LNP delivery platform for CRISPR RNPs
A lipid nanoparticle-based delivery platform designed to encapsulate and deliver pre-formed CRISPR protein–guide RNA complexes (RNPs) for in vivo genome editing applications.
Preclinical CRISPR-based therapeutic candidates
Therapeutic development efforts that pair the LNP delivery platform with active endonuclease proteins and target-specific guide RNAs to create candidate treatments for genetic diseases.
Services
Internal research and development of a non-viral LNP delivery platform and conduct of preclinical studies to generate proof-of-concept gene editing data.
Internal research and development of a non-viral LNP delivery platform and conduct of preclinical studies to generate proof-of-concept gene editing data.
Expertise Areas
- Gene delivery platform development
- Lipid nanoparticle formulation for in vivo use
- CRISPR ribonucleoprotein (RNP) delivery
- Preclinical in vivo gene editing studies
Key Technologies
- Lipid nanoparticles (LNPs)
- CRISPR ribonucleoprotein (RNP) delivery
- Guide RNA-based targeting
- Endonuclease protein delivery
News & Updates
Incisive Genetics Inc. announced it has raised $12 million CAD in an expanded seed round to support its research and development activities.
The company announced the closing of a $2.5 million seed investment led by notable investors.
Incisive Genetics announced the formation of its Scientific Advisory Board and the appointment of Dr. Michael R. Hayden as chairperson.
Incisive Genetics announced the appointment of Dr. Kevin Chow as President, bringing extensive industry experience.
The company closed the first phase of a $2 million angel investment to support its R&D activities.
Incisive Genetics Inc. announced it has raised $12 million CAD in an expanded seed round to support its research and development activities.
The company announced the closing of a $2.5 million seed investment led by notable investors.
Incisive Genetics announced the formation of its Scientific Advisory Board and the appointment of Dr. Michael R. Hayden as chairperson.
Incisive Genetics announced the appointment of Dr. Kevin Chow as President, bringing extensive industry experience.
The company closed the first phase of a $2 million angel investment to support its R&D activities.